Sonnet BioTherapeutics Holdings Beheer

Beheer criteriumcontroles 4/4

De CEO Sonnet BioTherapeutics Holdings is Pankaj Mohan, benoemd in Jan2015, heeft een ambtstermijn van 9.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 626.63K, bestaande uit 86% salaris en 14% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.14% van de aandelen van het bedrijf, ter waarde $ 26.76K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5 jaar en 5.1 jaar.

Belangrijke informatie

Pankaj Mohan

Algemeen directeur

US$626.6k

Totale compensatie

Percentage CEO-salaris	86.0%
Dienstverband CEO	9.8yrs
Eigendom CEO	1.1%
Management gemiddelde ambtstermijn	5yrs
Gemiddelde ambtstermijn bestuur	5.1yrs

Recente managementupdates

Recent updates

Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement

Oct 04

Sonnet BioTherapeutics announces 1-for-14 reverse stock split

Sep 16

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Jul 22

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Dec 19

Sonnet Bio issued U.S. patent for its albumin binding technology

Jun 08

Sonnet shares rise after completing licensing agreement with New Life Therapeutics

May 03

Sonnet BioTherapeutics reports FY results

Dec 17

Analyse CEO-vergoeding

Hoe is Pankaj Mohan's beloning veranderd ten opzichte van Sonnet BioTherapeutics Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$8m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	n/a	n/a	-US$14m
Sep 30 2023	US$635k	US$539k	-US$19m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	n/a	n/a	-US$29m
Sep 30 2022	US$1m	US$560k	-US$30m
Jun 30 2022	n/a	n/a	-US$29m
Mar 31 2022	n/a	n/a	-US$27m
Dec 31 2021	n/a	n/a	-US$25m
Sep 30 2021	US$792k	US$512k	-US$25m
Jun 30 2021	n/a	n/a	-US$67m
Mar 31 2021	n/a	n/a	-US$73m
Dec 31 2020	n/a	n/a	-US$69m
Sep 30 2020	US$2m	US$490k	-US$66m
Jun 30 2020	n/a	n/a	-US$20m
Mar 31 2020	n/a	n/a	-US$9m
Dec 31 2019	n/a	n/a	-US$7m
Sep 30 2019	US$548k	US$368k	-US$5m

Compensatie versus markt: De totale vergoeding ($USD 626.63K ) Pankaj } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 646.00K ).

Compensatie versus inkomsten: De vergoeding van Pankaj is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Pankaj Mohan (59 yo)

9.8yrs

Tenure

US$626,626

Compensatie

Dr. Pankaj Mohan, Ph.D. founded Sonnet BioTherapeutics Holdings, Inc. in 2015 and has since served as a member of its Board of Directors. Dr. Mohan has been Chairman of Sonnet BioTherapeutics Holdings, Inc...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Pankaj Mohan	Founder	9.8yrs	US$626.63k	1.14% $ 26.8k
John Cini	Chief Scientific Officer & Co-Founder	9.8yrs	US$419.66k	0.033% $ 780.6
Jay Cross	Chief Financial Officer	5.5yrs	US$406.81k	0.020% $ 465.5
Donald Griffith	Financial Controller & Director	5.8yrs	US$93.94k	0.0085% $ 198.7
Gael Hedou	Chief Operating Officer	no data	geen gegevens	geen gegevens
Susan Dexter	Chief Technical Officer	4.6yrs	geen gegevens	0.028% $ 653.9
Richard Kenney	Chief Medical Officer	3.6yrs	geen gegevens	geen gegevens
Manuel Dafonseca	Head of Clinical Operations	3.7yrs	geen gegevens	geen gegevens
Stephen McAndrew	Senior Vice President of Business Development	no data	geen gegevens	geen gegevens

5.0yrs

Gemiddelde duur

67.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SONN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Pankaj Mohan	Founder	9.8yrs	US$626.63k	1.14% $ 26.8k
Donald Griffith	Financial Controller & Director	9.6yrs	US$93.94k	0.0085% $ 198.7
Hossein Borghaei	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Lori McNeill	Independent Director	2.2yrs	US$64.33k	0.0031% $ 72.0
Albert Dyrness	Independent Director	5.1yrs	US$59.83k	0.024% $ 561.4
Nailesh Bhatt	Independent Director	6.3yrs	US$58.33k	0.025% $ 595.7
Guido Cavaletti	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Raghu Rao	Independent Director	5yrs	US$120.83k	0.29% $ 6.8k
Jason Bock	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Robert Wenham	Member of Scientific Advisory Board	2.2yrs	geen gegevens	geen gegevens

5.1yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SONN wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).

Sonnet BioTherapeutics Holdings Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Aug 31, 2023

Founder recently bought US$83k worth of stock

Sonnet BioTherapeutics Holdings Inc. Appoints Lori McNeill to the Board of Directors

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Jun 02, 2022

High number of new directors

Recent updates

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $5 million.

Sonnet BioTherapeutics Holdings, Inc. has filed a Follow-on Equity Offering.

Sonnet BioTherapeutics Regains Compliance with Nasdaq

Sonnet BioTherapeutics Holdings, Inc Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors

Nasdaq Hearings Panel Grants Sonnet BioTherapeutics Holdings, Inc. an Exception Until October 15, 2024 to Regain Compliance with the $1.00 Minimum Bid Price Requirement

Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities

Nasdaq Determines to Delist Sonnet BioTherapeutics Holdings Securities

Consensus EPS estimates upgraded to US$1.95 loss

Sonnet Biotherapeutics Holdings, Inc. to Present SB221 as A Trial in Progress At the Asco 2024 Annual Meeting

Sonnet BioTherapeutics Holdings, Inc. Announces Updated Clinical Data for Son-1010 as Monotherapy or Combined with an Anti-Pd-L1, Along with an Increase in the Dose-Escalation Target

Consensus revenue estimates increase by 42%, EPS downgraded

Second quarter 2024 earnings released: EPS: US$0.079 (vs US$7.55 loss in 2Q 2023)

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Sonnet BioTherapeutics Holdings Receives Non-Compliance Notice From Nasdaq

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance

Sonnet Biotherapeutics Announces FDA Acceptance of the Company's IND for the SB221 Clinical Trial of SON-1010 Combined with Atezolizumab in the US

Third quarter 2023 earnings released: US$0.13 loss per share (vs US$1.82 loss in 3Q 2022)

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Aug 31, 2023

Sonnet Biotherapeutics Holdings, Inc. Announces Regulatory Approval for Initiation of A Clinical Trial of Son-1010 Combined with Atezolizumab

Founder recently bought US$83k worth of stock

Price target decreased by 13% to US$10.35

Consensus revenue estimates decrease by 50%, EPS upgraded

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $14.999777 million.

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering.

Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates

Sonnet BioTherapeutics Holdings, Inc. Announces Pharmacokinetic and Pharmacodynamic Data in A Phase 1 Dose-Escalation Trial of SON-1010

Price target decreased to US$25.00

Sonnet BioTherapeutics Holdings, Inc. Announces Interim Data in Two Phase 1 Dose-Escalation Trials of Son-1010

Nasdaq Listing Qualifications Staff Grants an Extension to Sonnet

Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Sonnet BioTherapeutics regains compliance with Nasdaq's minimum bid price requirement

Sonnet BioTherapeutics Holdings Inc. Appoints Lori McNeill to the Board of Directors

Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010

Sonnet BioTherapeutics announces 1-for-14 reverse stock split

Sonnet BioTherapeutics Holdings Receives Non-Compliance Letter from Nasdaq

Consensus forecasts updated

Sonnet BioTherapeutics Holdings, Inc. announced that it has received $2.25 million in funding

Sonnet gets clearance to start phase 1b/2a trial of SON-080 in Australia

Price target decreased to US$2.25

Sonnet BioTherapeutics Holdings, Inc., Annual General Meeting, Jun 02, 2022

Nasdaq Grants Extension to Sonnet BioTherapeutics Holdings Till October 03, 2022 to Regain Compliance

We're A Little Worried About Sonnet BioTherapeutics Holdings' (NASDAQ:SONN) Cash Burn Rate

Sonnet BioTherapeutics Holdings, Inc. Selects Novel Development Candidate After Completing Comparative Studies in a Mouse Melanoma Model

Sonnet BioTherapeutics Holdings, Inc. has completed a Follow-on Equity Offering.

High number of new directors

Sonnet Bio issued U.S. patent for its albumin binding technology

Sonnet shares rise after completing licensing agreement with New Life Therapeutics

New 90-day low: US$2.07

New 90-day high: US$3.10

Sonnet BioTherapeutics reports FY results

New 90-day high: US$2.98

New 90-day low: US$2.42

New 90-day low - US$2.46

New 90-day low - US$2.63

SONNET BioTherapeutics, Inc. completed the acquisition of Chanticleer Holdings, Inc. (NasdaqCM:BURG) in a reverse merger transaction.

Sonnet BioTherapeutics Holdings, Inc. completed the acquisition of Relief Therapeutics SA from Relief Therapeutics Holding AG (SWX:RLF).

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd